secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001787306-22-000057
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints Neha Krishnamohan to Board of Directors and audit committee
----------------------------------------------------------------------------

- Board expanded from 9 to 10; Krishnamohan appointed Class III director and audit committee member.
- Krishnamohan is CFO and EVP of Corporate Development at Kinnate Biopharma; previously VP at Goldman Sachs.
- Received stock option for 29,482 shares vesting over three years; eligible for $40,000 annual retainer plus $10,000 for audit committee.
- Krishnamohan worked on Arcutis' 2020 IPO while at Goldman Sachs.
- Appointment effective September 2, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000057/0001787306-22-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000057/arqt-20220902.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer